The Speciality Medicines IPO was subscribed 1.48 times on the last day. The retail quota was subscribed over 8.99 times, NII was subscribed over 25.41 times, and QIB was subscribed 6.57 times, respectively.
Speciality Medicines IPO Listing gains
| Listing Date | March 30, 2026 |
| BSE Code | 544738 |
| ISIN Code | INE0R0M01014 |
| Offer Price | ā¹124 |
| Face Value | ā¹10 |
| Listing Price | ā¹124 |
Details About Speciality Medicines IPO
Speciality Medicines got approval from SEBI for an IPO of around ā¹29.14 crores, via fresh issues of ā¹29.14 crores with a face value of ā¹10 each. Further, Speciality Medicines had a price band of ā¹117 to ā¹124 per share.
In the Speciality Medicines IPO, 2,000 shares were offered in 2 lot sizes for the retail minimum and maximum categories as well.
3,000 shares were in 3 lot sizes for the S-HNI Minimum category.
S-HNI maximum has 8,000 shares in 8 lot sizes.
B-HNI has 9,000 shares in 9 lot sizes.
To invest in the Speciality Medicines IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum and maximum investment of ā¹2,48,000.
- S-HNI (Min): Minimum investment of ā¹3,72,000.
- S-HNI Maximum: investment of ā¹9,92,000.
- B-HNI Minimum: investment of ā¹11,16,000.
Speciality Medicines IPOās Subscription Duration
The opening date of Speciality Medicines’ IPO was on March 20, 2026, and the closing date was on March 24, 2026.
The allotment date of the Speciality Medicines IPO was on March 25, 2026, and the investors will receive a refund on March 27, 2026.
Speciality Medicines is set to be listed on March 30, 2026.
About Speciality Medicines Company
One of the leading companies,ā Speciality Medicinesā was founded in 2021 and started a business of marketing and distribution of finished formulations of speciality pharmaceutical products, comprising high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology, and rare diseases.
The company works in two main ways:
- (a) making finished medicines for other companies to sell in international markets, and
- (b) selling and distributing special pharmaceutical products that it gets from other suppliers.
